Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer
A Phase Ib clinical trial has shown that the targeted therapy firmonertinib is effective for patients with specific EGFR PACC-mutated non-small cell lung cancer. Researchers suggest that grouping mutations by protein structure rather than gene location could lead to more precise and effective treatment strategies.
Why it matters
This research offers a potential breakthrough for patients with rare lung cancer mutations who previously had limited treatment options.
by University of Texas MD Anderson Cancer Center
edited by Sadie Harley , reviewed by Alexander Pol
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Molecular modeling illustrates how firmonertinib, depicted in magenta, binds to PACC-mutant EGFR proteins. Credit: The University of Texas MD Anderson Cancer Center For patients with EGFR PACC-mutated non-small cell lung cancer (NSCLC), the targeted therapy firmonertinib achieved durable antitumor activity in a Phase Ib trial led by researchers at The University of Texas MD Anderson Cancer Center, supporting an approach to selecting treatments based on the structural features of uncommon EGFR mutations.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in